How pediatric mental health prescribing differs from adult and why it matters

What pediatric mental health prescribing looks like

Pediatric mental health spans diagnoses (ADHD, depression, anxiety disorders, autism spectrum disorder, OCD, oppositional defiant disorder, conduct disorder, schizophrenia in adolescents, others) with substantial prevalence in children and adolescents. The therapeutic class includes:

• Stimulants and ADHD therapy: The most-prescribed class in pediatric mental health, with extensive but evolving safety and outcome evidence
• SSRIs and adjacent antidepressants: Used in pediatric depression and anxiety, with the FDA boxed warning regarding suicidality in younger patients shaping prescribing
• Atypical antipsychotics: Used in autism-associated irritability, in early-onset psychotic illness, and in adjunct depression treatment
• Mood stabilisers: Used in pediatric bipolar disorder and adjacent indications
• Novel mechanisms: Including non-stimulant ADHD agents and emerging programs

Why pediatric prescribing differs from adult

The principal structural differences:

• Evidence base: Pediatric clinical trials are operationally more difficult than adult trials. The evidence base for pediatric prescribing is thinner, and much pediatric prescribing relies on extrapolation from adult evidence with appropriate adjustment for pharmacokinetic and developmental considerations
• Regulatory framework: The FDA Pediatric Research Equity Act and the EMA Paediatric Investigation Plan framework require sponsors to develop pediatric data for adult-approved assets in many indications. The framework provides incentives but also imposes operational requirements
• Safety frame: Pediatric safety considerations include developmental impact, growth and metabolic effects, and long-term outcome considerations that adult prescribing does not face. The risk-benefit calculation is different
• Access structure: Pediatric mental health access requires paediatric psychiatry specialty access (a workforce that is materially undersupplied globally), school-based screening and referral pathways, and parent-and-caregiver coordination

What this means for commercial planning

For sponsors of mental health assets with pediatric-relevant indications:

• Pediatric expansion is an explicit commercial decision. Some assets are positioned for pediatric expansion from initial development; others position post-adult-approval; the path differs
• The pediatric evidence-development timeline is typically longer than the adjacent adult timeline. Commercial planning has to anticipate the staggered access timeline
• The pediatric workforce gap is the principal operational constraint on pediatric mental health commercial uptake. Engagement with workforce development, school-based screening initiatives, and primary care pediatrician training is leveraged

What we are watching

• Late-stage paediatric mental health pipeline programs and the rate of pediatric-specific approvals
• Pediatric prescribing trends across the major drug classes and what they tell us about access pathway maturation
• Adjacent pediatric indications (autism, neurodevelopmental disorders, eating disorders) where the therapeutic landscape is rapidly evolving